Matt Katz - PharmChem Chief Officer
| PCHM Stock | USD 3.10 0.04 1.31% |
Insider
Matt Katz is Chief Officer of PharmChem
| Phone | 855-458-4100 |
| Web | https://www.pharmchek.com |
PharmChem Management Efficiency
The company has return on total asset (ROA) of (0.0537) % which means that it has lost $0.0537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2367) %, meaning that it created substantial loss on money invested by shareholders. PharmChem's management efficiency ratios could be used to measure how well PharmChem manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jessica Mega | Danaher | 46 | |
| Dan Welch | Waters | 58 | |
| Pardis Sabeti | Danaher | 45 | |
| Carissa Rollins | Illumina | 55 | |
| Stephanie Campos | Illumina | N/A | |
| Jianqing Bennett | Waters | 55 | |
| Padraig McDonnell | Agilent Technologies | 49 | |
| Susan Rataj | Agilent Technologies | 63 | |
| Kevin Pegels | Illumina | 57 | |
| Susan Tousi | Illumina | 55 | |
| JoseCarlos GutierrezRamos | Danaher | 63 | |
| Scott Ericksen | Illumina | 52 | |
| Kevin Kempskie | Waters | N/A | |
| Christopher Bouda | Danaher | N/A | |
| Pearl Huang | Waters | 62 | |
| Jennifer Honeycutt | Danaher | 54 | |
| John Ballbach | Waters | 60 | |
| Keeley Aleman | Waters | 47 | |
| Alexander MD | Illumina | 47 | |
| Jonathan Pratt | Waters | 54 | |
| Katharine Knobil | Agilent Technologies | 56 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | -0.0537 |
PharmChem Management Team
Elected by the shareholders, the PharmChem's board of directors comprises two types of representatives: PharmChem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PharmChem. The board's role is to monitor PharmChem's management team and ensure that shareholders' interests are well served. PharmChem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PharmChem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shana Veale, VP CFO | ||
| Matt Katz, Chief Officer | ||
| Kerri Wagner, Chief Officer |
PharmChem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PharmChem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.0537 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | (0.06) % | |||
| Current Valuation | 17.56 K | |||
| Price To Earning | (2.30) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0006 X | |||
| Revenue | 26.45 M | |||
| Gross Profit | 5.86 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in PharmChem Pink Sheet
PharmChem financial ratios help investors to determine whether PharmChem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PharmChem with respect to the benefits of owning PharmChem security.